In Q3FY21, its cumulative disbursements went beyond Rs 2,000 crore. In the same quarter, the value of AUM stood at Rs 1,127 crore, which is a 15 per cent increase over its previous quarter.

Industrial biotechnology company, Praj Industries Ltd announced on Tuesday that it has bagged a prestigious breakthrough order to set up compressed biogas (CBG) project from Hindustan Petroleum Corporation Limited (HPCL).

The Ahmedabad-based company informed the bourses that it has received a letter of acceptance (LoA) amounting to Rs 1,491.34 crore (exclusive of GST) to construct medical colleges and hospitals at multiple locations in Uttar Pradesh.

The company’s marketing partner BPI will launch Everolimus tablets in the strengths of 2.5 mg, 5 mg, and 7.5 mg in the near term.

The company received the order for waste heat recovery boilers from the cement industry while its capacity makes it the largest in the world.

The company has received the order from Bharat Sanchar Nigam Limited (BSNL) for the commissioning of point-to-point links.

This is a strategic acquisition as the location of GPL in the north of Andhra Pradesh complements the company’s recent acquisition of the Port of Krishnapatnam that serves the south of AP.

The company announced the addition of two residential plots in Sanpada (Navi Mumbai) from City & Industrial Development Corporation (CIDCO).

The subsidiary of Biocon Ltd i.e. Biocon Biologics announced on Monday that it has received CHMP approval to market Abevmy, which is a biosimilar to Avastin.

The company has approved the proposal for the buyback of fully paid-up equity shares for an aggregate amount, not exceeding Rs 150 crore, which is 5.05 per cent of the total paid-up equity share capital.

The drug may help improve mood and feelings of well-being, relieve anxiety and tension as well as increase energy level.

The drug will be manufactured in the company’s Hyderabad facility, which is expected to be launched in the near term.